Key Laboratory of Molecular Medicine and Biotherapy, School of Life Sciences, Beijing Institute of Technology, Beijing 100081, P. R. China.
J Mater Chem B. 2023 Sep 13;11(35):8315-8326. doi: 10.1039/d3tb00668a.
With increasing demand for the accurate and safe treatment of cancer, non-invasive photodynamic therapy (PDT) has received widespread attention. However, most conventional photosensitizers are typically excited by short-wavelength visible light (400-700 nm), thus substantially hindering the penetration of light and the therapeutic effectiveness of the PDT procedure. Fortunately, near-infrared (NIR) light (>700 nm), in particular, light in the second near-infrared region (NIR-II, 1000-1700 nm) has a higher upper radiation limit, greater tissue tolerance, and deeper tissue penetration compared with traditional short-wavelength light excitation, and shows considerable potential in the clinical treatment of cancer. Therefore, it is of paramount importance and clinical value to develop photosensitizers that are excited by NIR-II light. In this review, for the first time we focus completely on recent progress made with various NIR-II photosensitizers for cancer treatment PDT, and we briefly present the ongoing challenges and prospects of currently developed NIR-II photosensitizers for clinical practice in the near future. We believe that the above topics will inspire broad interest in researchers from interdisciplinary fields that include chemistry, materials science, pharmaceuticals, and clinical medicine, and provide insightful perspectives for exploiting new NIR-II photosensitizers for biomedical applications.
随着人们对癌症精确和安全治疗的需求不断增加，非侵入性光动力疗法（PDT）受到了广泛关注。然而，大多数传统的光敏剂通常被短波长可见光（400-700nm）激发，这极大地限制了光的穿透和 PDT 治疗的效果。幸运的是，近红外（NIR）光（>700nm），特别是近红外二区（NIR-II，1000-1700nm）光的辐射上限更高，组织耐受性更强，组织穿透更深，与传统的短波长光激发相比，在癌症的临床治疗中显示出相当大的潜力。因此，开发近红外二区光激发的光敏剂至关重要，具有重要的临床价值。在这篇综述中，我们首次全面关注了用于癌症治疗 PDT 的各种近红外二区光敏剂的最新进展，并简要介绍了目前开发的近红外二区光敏剂在不久的将来应用于临床实践所面临的挑战和前景。我们相信，上述主题将激发来自化学、材料科学、药物学和临床医学等跨学科领域的研究人员的广泛兴趣，并为开发用于生物医学应用的新型近红外二区光敏剂提供有见地的观点。
